Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
10.66 USD | +2.80% | +7.63% | +69.44% |
Financials (USD)
Sales 2024 * | 604K | Sales 2025 * | 8.03M | Capitalization | 269M |
---|---|---|---|---|---|
Net income 2024 * | -99M | Net income 2025 * | -93M | EV / Sales 2024 * | 445 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 33.4 x |
P/E ratio 2024 * |
-2.69
x | P/E ratio 2025 * |
-3.43
x | Employees | 122 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.51% |
Latest transcript on Inovio Pharmaceuticals, Inc.
1 day | +3.49% | ||
1 week | +7.63% | ||
Current month | -25.29% | ||
1 month | -10.76% | ||
3 months | +48.97% | ||
6 months | +104.73% | ||
Current year | +69.44% |
Managers | Title | Age | Since |
---|---|---|---|
Jacqueline Shea
CEO | Chief Executive Officer | 58 | 19-03-24 |
Peter Kies
DFI | Director of Finance/CFO | 60 | 02-05-31 |
Chief Tech/Sci/R&D Officer | - | 07-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Simon Benito
CHM | Chairman | 79 | 03-11-30 |
Lota Zoth
BRD | Director/Board Member | 64 | 17-12-31 |
Jay Shepard
BRD | Director/Board Member | 66 | 20-01-14 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.04% | 0 M€ | 0.00% | - | |
0.04% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-23 | 10.37 | +3.49% | 242 734 |
24-04-22 | 10.02 | +3.51% | 335,745 |
24-04-19 | 9.68 | -5.10% | 353,700 |
24-04-18 | 10.2 | -7.86% | 401,381 |
24-04-17 | 11.07 | +14.89% | 706,286 |
Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+69.44% | 269M | |
+3.13% | 43.43B | |
+48.83% | 41.69B | |
+8.49% | 41.31B | |
-10.82% | 27.14B | |
+8.26% | 25.28B | |
-23.69% | 18.47B | |
+1.58% | 12.33B | |
+32.83% | 12.59B | |
+6.63% | 11.03B |
- Stock Market
- Equities
- INO Stock